List of Excipients in Branded Drug GUANFACINE HYDROCHLORIDE

Generic Drugs Containing GUANFACINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Atlantic Biologicals Corps	guanfacine	17856-0711	CELLULOSE, MICROCRYSTALLINE
Atlantic Biologicals Corps	guanfacine	17856-0711	STARCH, CORN
Atlantic Biologicals Corps	guanfacine	17856-0711	STEARIC ACID
TWi Pharmaceuticals Inc	guanfacine	24979-198	ANHYDROUS LACTOSE
TWi Pharmaceuticals Inc	guanfacine	24979-198	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in GUANFACINE HYDROCHLORIDE?

# Of NDCs	Excipient
5	ANHYDROUS LACTOSE
14	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 1--ALUMINUM LAKE
4	LACTOSE MONOHYDRATE
4	SILICON DIOXIDE

Guanfacine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Guanfacine hydrochloride is a mature, low-cost active pharmaceutical ingredient with two established dosage-form markets: immediate-release tablets for hypertension and extended-release tablets for attention-deficit/hyperactivity disorder (ADHD). The strongest commercial opportunities are formulation-led rather than molecule-led. Differentiation can come from controlled release, pediatric acceptability, liquid dosing, orally disintegrating tablets, multiparticulates, and manufacturing platforms that improve dose uniformity at the drug's low-strength levels.

What is the regulatory and commercial status of guanfacine hydrochloride?

Guanfacine hydrochloride is an FDA-approved alpha-2A adrenergic receptor agonist. Immediate-release guanfacine hydrochloride tablets are marketed for hypertension under the Tenex label. Extended-release guanfacine tablets are marketed for ADHD under the Intuniv label.

Attribute	Immediate-release guanfacine HCl	Extended-release guanfacine
Primary brand	Tenex	Intuniv
Main indication	Hypertension	ADHD
Typical strengths	1 mg, 2 mg	1 mg, 2 mg, 3 mg, 4 mg
Administration	Once or twice daily, depending on regimen	Once daily
Regulatory route for generics	ANDA	ANDA, subject to product-specific equivalence requirements
Drug class	Alpha-2 adrenergic agonist	Alpha-2A adrenergic agonist
Biosimilar pathway	Not applicable	Not applicable
Core commercial issue	Low-cost commoditization	Differentiated release profile and pediatric usability

Intuniv was approved by the FDA in September 2009 as an extended-release tablet for ADHD. The label specifies once-daily administration and warns against substituting the extended-release product for immediate-release guanfacine on a milligram-per-milligram basis because the pharmacokinetic profiles differ (FDA, 2023a).

Immediate-release guanfacine is a generic market. Extended-release guanfacine is also available from multiple generic manufacturers, reducing the value of legacy product patents. Commercial returns now depend on manufacturing cost, supply reliability, dosage-form differentiation, and access to institutional or pediatric channels.

What excipients are used in guanfacine hydrochloride products?

Guanfacine formulations use conventional tablet excipients, but the low dose and pharmacologically active nature of the compound make content uniformity, blend segregation, and dissolution control important.

Immediate-release excipient profile

Commercial immediate-release guanfacine tablets generally use combinations of:

• Lactose monohydrate or another soluble filler
• Microcrystalline cellulose
• Pregelatinized starch or starch
• Povidone or another binder
• Crospovidone or sodium starch glycolate
• Magnesium stearate
• Colloidal silicon dioxide
• Film-coating polymers, pigments, and plasticizers

The immediate-release design objective is rapid disintegration and reproducible dissolution. Since guanfacine hydrochloride is administered at low milligram strengths, a direct-compression formulation may be vulnerable to segregation if the active pharmaceutical ingredient has a substantially different particle-size distribution or density from the filler system.

Extended-release excipient profile

The Intuniv label identifies a matrix-based tablet containing common hydrophilic and processing excipients, including hypromellose, lactose monohydrate, microcrystalline cellulose, povidone, crospovidone, magnesium stearate, and colloidal silicon dioxide. The precise release behavior depends on polymer grade, polymer loading, granulation conditions, tablet hardness, and coating parameters (FDA, 2023a).

A development program should treat the excipient system as a release platform, not as a simple list of ingredients. The main variables are:

Formulation variable	Commercial effect
Hypromellose viscosity grade	Controls gel formation and drug diffusion
Polymer concentration	Changes release duration and dose dumping risk
Lactose-to-cellulose ratio	Affects porosity, compressibility, and wetting
Povidone level	Affects granule strength and dissolution
Lubricant level	Excess magnesium stearate can slow wetting and dissolution
Tablet hardness	Influences erosion and release reproducibility
Coating weight	Can improve appearance and handling but may alter hydration
Particle-size distribution	Affects blend uniformity and content uniformity

How should an excipient strategy be designed for guanfacine hydrochloride?

The preferred excipient strategy depends on the commercial objective.

Strategy 1: Low-cost immediate-release generic

For a standard immediate-release tablet, the formulation should prioritize:

1. Robust content uniformity at 1 mg strength.
2. Direct compression or low-complexity wet granulation.
3. Rapid disintegration.
4. Low sensitivity to lubricant mixing time.
5. Excipient availability from multiple qualified suppliers.
6. Compatibility with high-speed tableting.

A dry-coating or ordered-mixture approach may be useful where guanfacine particles are difficult to distribute uniformly. Microcrystalline cellulose can provide compactibility, while lactose improves tablet mass and dissolution. A small amount of colloidal silicon dioxide can improve flow, but excessive silica can impair compaction and create handling issues.

For a low-cost product, the excipient system should avoid dependence on a single specialty polymer or proprietary co-processed excipient unless that material materially improves yield or bioequivalence performance.

Strategy 2: Extended-release matrix tablet

The most practical platform for extended-release guanfacine is a hydrophilic matrix using hypromellose. The formulation target is a controlled release profile that remains consistent across:

• Gastric and intestinal pH
• Fed and fasted conditions
• Tablet hardness variation
• Manufacturing-scale changes
• API particle-size variation
• Moderate differences in gastrointestinal transit

A matrix formulation can be tuned through polymer viscosity, particle size, polymer fraction, filler selection, and compression force. The principal technical risk is an early release phase that produces excessive exposure followed by a prolonged tail. This is particularly relevant for guanfacine because excessive systemic exposure can cause somnolence, hypotension, bradycardia, and syncope. The FDA label includes warnings concerning blood pressure, heart rate, sedation, and withdrawal-related effects (FDA, 2023a).

Strategy 3: Pediatric liquid formulation

A liquid product could address swallowing difficulty, dose titration, and administration through specialty pharmacies. The principal excipient issues are taste, chemical stability, microbial control, and dose uniformity after storage.

Potential excipient classes include:

• Purified water as the vehicle
• Glycerin or sorbitol for mouthfeel and viscosity
• Hydroxyethylcellulose or xanthan gum for suspension control
• Sucralose, saccharin sodium, or fruit flavors for taste masking
• Citrate or phosphate buffers
• Preservatives such as potassium sorbate or sodium benzoate, subject to compatibility and pediatric acceptability
• Wetting agents where necessary

Guanfacine's bitter or medicinal taste creates a meaningful product-development barrier. A suspension may provide flexible dosing but requires validated redispersibility and shake instructions. A clear solution is easier to dose but may create greater taste exposure and stability demands.

A 505(b)(2) strategy could be commercially relevant if the applicant develops a differentiated liquid product with a new concentration, dosing device, stability profile, or administration route. The pathway would not eliminate the need to address clinical bridging and labeling requirements.

Strategy 4: Orally disintegrating tablet

An orally disintegrating tablet could target children and adolescents who cannot swallow conventional tablets. The product should use a low-mass, fast-wetting platform based on:

• Mannitol or isomalt for mouthfeel
• Crospovidone or sodium starch glycolate for rapid disintegration
• Microcrystalline cellulose or silicified microcrystalline cellulose for structure
• A taste-masking coating or ion-exchange resin
• Low levels of magnesium stearate
• A moisture-protective package

The low dose of guanfacine is favorable for an orally disintegrating tablet. The principal development risk is not tablet size but taste. A polymer film, lipid barrier, cyclodextrin complex, or ion-exchange resin may reduce immediate bitterness, although each approach can affect dissolution and bioavailability.

Strategy 5: Sprinkle or multiparticulate product

A coated-pellet or mini-tablet product could be administered with soft food. The release-controlling layer may use ethylcellulose, ammonio methacrylate copolymers, or other insoluble or pH-responsive polymers.

This platform could create a differentiated pediatric product, but it carries higher manufacturing and regulatory complexity. The label would need to control the food vehicle, administration method, chewing restrictions, and dose recovery. Multiparticulates also create more opportunities for process variation in coating weight, agglomeration, and content uniformity.

What formulation patents protect guanfacine hydrochloride?

The guanfacine hydrochloride active ingredient and basic immediate-release tablet technology are mature. The commercially relevant intellectual-property opportunities are concentrated in:

• Extended-release matrix architecture
• Specific polymer combinations
• Multiparticulate release systems
• Taste-masked pediatric formulations
• Liquid suspensions or solutions
• Orally disintegrating tablets
• Dosing regimens and titration methods
• Manufacturing controls that produce a defined dissolution profile

Legacy Intuniv patents and related formulation rights have been central to generic litigation and launch timing. The remaining practical value of older patents is limited where they have expired, been designed around, or become less relevant because multiple generic products have entered the market. Current Orange Book entries, patent expiration dates, and litigation records should be assessed product by product because listings can change with FDA updates and delisting activity (FDA, 2024).

How strong is the patent estate for guanfacine extended-release products?

The patent estate is generally stronger for a narrowly defined formulation than for guanfacine hydrochloride itself. A broad claim covering guanfacine in a sustained-release tablet would face substantial prior-art pressure. A more defensible estate could combine:

• A specific polymer grade and concentration range
• A defined dissolution profile
• A manufacturing process that produces a reproducible matrix
• A pediatric administration method
• A taste-masking architecture
• A stability profile under specified packaging conditions

Patent strength depends on claim breadth, clinical relevance, reproducibility, and the availability of non-infringing alternatives. A formulation claim that can be avoided by changing polymer viscosity or compression conditions has weaker commercial blocking power than a claim tied to a clinically meaningful release profile that is difficult to reproduce through alternative technology.

When does guanfacine hydrochloride lose exclusivity?

Immediate-release guanfacine has long lost practical market exclusivity. The Tenex product is commercially mature, and generic immediate-release tablets are widely available.

Extended-release guanfacine also faces generic competition. Intuniv's historical regulatory exclusivity and formulation patents no longer provide the same commercial protection as they did before generic entry. The relevant exclusivity categories are:

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Not relevant to current guanfacine products
Orphan exclusivity	Not applicable
Pediatric exclusivity	Historical, not a current barrier to routine entry
Formulation patent protection	Potentially relevant only for unexpired, enforceable claims
Method-of-use patents	Narrower value and vulnerable to carve-outs
Regulatory exclusivity for a new 505(b)(2) product	Potentially available for a genuinely differentiated product

A new dosage form may obtain regulatory benefits, but a 505(b)(2) applicant must still manage patent certifications, labeling strategy, clinical bridging, and potential litigation. A new excipient combination alone does not guarantee meaningful exclusivity.

What Paragraph IV challenges and litigation affect guanfacine products?

Generic applicants for extended-release guanfacine have historically used ANDA patent certifications, including Paragraph IV challenges, to address listed patents associated with Intuniv. These disputes generally concerned extended-release formulation and use claims rather than ownership of the guanfacine molecule itself.

The commercial implications of a Paragraph IV filing include:

• Potential 30-month stay of ANDA approval under the Hatch-Waxman framework
• At-risk launch exposure
• Possible 180-day exclusivity for a first successful Paragraph IV filer
• Settlement terms affecting launch timing
• Labeling carve-outs for protected indications
• Uncertainty over whether a generic can match the reference product's release profile

A patent review should separate three issues: whether the patent remains listed, whether the claims remain enforceable, and whether the generic product would infringe. A historical lawsuit or settlement does not establish current blocking power.

What is the Orange Book status of guanfacine hydrochloride?

FDA Orange Book analysis should distinguish reference products from active generic listings. For guanfacine:

• Immediate-release tablets are associated with the Tenex reference product and multiple ANDA products.
• Extended-release tablets are associated with the Intuniv reference product and generic equivalents.
• Orange Book patent listings, pediatric exclusivity, therapeutic-equivalence codes, and reference-product designations should be verified against the current FDA database before a filing or launch decision.
• A formulation developer should review both active patents and discontinued or delisted entries because patent history can affect Paragraph IV strategy and litigation risk (FDA, 2024).

The Orange Book does not capture every potentially relevant patent. Manufacturing, device, packaging, trade-secret, and process patents may sit outside the listed-product framework.

What generic entry risks exist for guanfacine hydrochloride?

Immediate-release risk

Immediate-release entry risk is high because:

• The active ingredient is old and widely characterized.
• Conventional excipients are available from many suppliers.
• The dosage form is simple.
• Bioequivalence is generally more straightforward than for extended-release products.
• Price competition is intense.

The principal operational risks are API supply, low-strength content uniformity, dissolution variability, and small-volume economics.

Extended-release risk

Extended-release entry risk is also high at the market level but more technically complex. Key risks include:

• Failure to match the reference dissolution profile
• Food-effect differences
• Dose dumping under alcohol or altered gastrointestinal conditions
• Excessive sedation or cardiovascular exposure
• Manufacturing changes that alter release behavior
• Pediatric adherence and administration issues
• Competition from several approved generic manufacturers

The best commercial defense is a product that creates switching friction through usability, supply reliability, or differentiated dosing rather than one that depends solely on legacy patent claims.

What commercial opportunities exist for guanfacine excipients?

Pediatric ADHD products

Pediatric ADHD is the most attractive segment for formulation differentiation. Opportunities include:

• Pleasant-tasting oral liquids
• Low-volume concentrated solutions
• Orally disintegrating tablets
• Sprinkle formulations
• Flexible titration strengths
• Unit-dose sachets
• Calendar packaging and adherence-oriented presentations

The excipient package should be selected around pediatric tolerability. High sugar loads, ethanol, excessive sodium, and poorly tolerated preservatives can reduce product acceptance and complicate global registration.

Combination products

Guanfacine could be evaluated in combination products with stimulant or nonstimulant ADHD therapies, but the regulatory and clinical burden is materially higher. The commercial rationale would need to include improved symptom control, reduced stimulant dose, or management of stimulant-associated adverse effects. A combination product could create stronger exclusivity than a reformulated guanfacine product, but it would also require more extensive clinical evidence.

Compounded and specialty pharmacy products

Compounded guanfacine liquids may meet local dosing needs, but a commercially manufactured product can compete through validated stability, consistent concentration, dosing syringes, child-resistant packaging, and insurance coverage. This opportunity is strongest where clinicians need dose flexibility not provided by standard tablets.

Global and emerging markets

In markets where ADHD diagnosis and treatment are expanding, an affordable extended-release or pediatric liquid product could be positioned below branded imported products. Regulatory filings would need to account for local excipient restrictions, permitted colors and flavors, preservative standards, and packaging requirements.

How does guanfacine compare with competing ADHD drugs?

Product class	Example	Excipient opportunity	Patent and competition profile
Alpha-2 agonist	Guanfacine ER	Liquid, ODT, sprinkle, matrix release	Mature generic competition
Alpha-2 agonist	Clonidine ER	ER matrix and pediatric formulations	Generic competition, different pharmacology
Stimulant	Methylphenidate ER	Abuse deterrence, multiparticulates, release technologies	Multiple formulation estates
Stimulant	Amphetamine ER	Prodrug and abuse-deterrent systems	Stronger branded formulation differentiation in some products
Nonstimulant	Atomoxetine	Capsule and liquid development	Mature molecule, different safety and efficacy profile
Nonstimulant	Viloxazine ER	Capsule release technology	Newer commercial and patent profile

Guanfacine's advantage is a well-understood pediatric use case and low API cost. Its disadvantage is limited molecule-level exclusivity and substantial generic competition. A successful product must improve administration, tolerability, or adherence.

What manufacturing and IP barriers matter most?

The main manufacturing barriers are low-dose uniformity and controlled-release reproducibility. The most valuable know-how may involve:

• API deagglomeration
• Ordered mixing or carrier-based dilution
• Granulation endpoint control
• Polymer distribution within the matrix
• Tablet hardness and porosity control
• Coating uniformity
• In-process dissolution testing
• Moisture-control packaging
• Scale-up without shifting the release profile

These process controls can support trade-secret protection even where patent claims are narrow. However, trade secrets are weaker against independent development and reverse engineering than patents. A layered strategy should combine formulation patents, process patents where defensible, supplier qualification, analytical methods, and manufacturing know-how.

Key Takeaways

• Guanfacine hydrochloride is a mature API with high generic competition.
• Immediate-release products offer limited formulation differentiation and low patent leverage.
• Extended-release products remain the most important formulation segment, but release-profile matching is technically demanding.
• Hypromellose matrix systems are the primary platform for once-daily guanfacine extended release.
• Pediatric liquids, orally disintegrating tablets, and sprinkle products offer the clearest commercial opportunities.
• Taste masking, low-dose content uniformity, and dose flexibility should drive excipient selection.
• Legacy Intuniv patents and Paragraph IV disputes are historical precedents, not automatic current barriers.
• A new product's strongest protection is likely to come from a clinically useful dosage form, defined release performance, manufacturing know-how, and targeted regulatory strategy.
• Guanfacine has no biosimilar pathway because it is a small-molecule drug.
• Current Orange Book listings and patent status must be reviewed before committing to an ANDA, 505(b)(2), licensing, or launch plan.

FAQs About Guanfacine Hydrochloride Excipient and Patent Strategy

Can guanfacine hydrochloride be formulated as a stable oral solution?

Yes. A stable oral solution is technically feasible, but pH, light exposure, taste, preservative compatibility, microbial control, and container-closure performance require validation. A suspension may provide a more practical alternative where taste or solubility limits the solution design.

Which excipient is most important for guanfacine extended release?

Hypromellose is usually the central release-controlling excipient in a hydrophilic matrix tablet. Its viscosity grade, concentration, particle size, and distribution can materially change dissolution and pharmacokinetics.

Is an orally disintegrating guanfacine tablet commercially differentiated?

Yes, if it delivers acceptable taste, rapid disintegration, dose accuracy, and bioequivalence without creating new safety or administration concerns. The commercial value is higher in pediatric populations with swallowing difficulty.

Can a guanfacine generic use different excipients from Intuniv?

Yes. An ANDA product generally may use different inactive ingredients if it meets applicable safety, pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. Differences that affect absorption, release, or tolerability may require additional regulatory justification.

Does guanfacine hydrochloride have biosimilar competition?

No. Guanfacine hydrochloride is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, including ANDAs, rather than the biosimilar framework.

References

1. U.S. Food and Drug Administration. (2023a). Intuniv (guanfacine hydrochloride) extended-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2023b). Tenex (guanfacine hydrochloride) tablets: Prescribing information. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly variable drug products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

6. U.S. Food and Drug Administration. (2023c). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/